Rucaparib for BRCA1/2-mutated pretreated ovarian cancer: reflections from the ARIEL4 trial

Lancet Oncol. 2022 Apr;23(4):440-441. doi: 10.1016/S1470-2045(22)00150-4. Epub 2022 Mar 14.

Author

Dearbhaile M O'Donnell¹

Affiliation

¹ Department of Medical Oncology, St James's Hospital, Dublin D08 NHY1, Ireland. Electronic address: dodonnell@stjames.ie.

PMID: 35298905
DOI: 10.1016/S1470-2045(22)00150-4

No abstract available

Publication types

Comment

MeSH terms

BRCA1 Protein / genetics
Carcinoma, Ovarian Epithelial
Clinical Trials as Topic
Female
Humans
Indoles* / therapeutic use
Ovarian Neoplasms* / drug therapy
Ovarian Neoplasms* / genetics

Substances

BRCA1 Protein
BRCA1 protein, human
Indoles
rucaparib